High-throughput screening identified the imidazo[1,2-a]pyridine and bisanilinopyrimidine series as inhibitors of the cyclin-dependent kinase CDK4. Comparison of their experimentally-determined binding modes and emerging structure-activity trends led to the development of potent and selective imidazo[1,2-a]pyridine inhibitors for CDK4 and in particular CDK2.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/s0960-894x(03)00638-3 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!